Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 10/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8115629 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4153023 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8102432 | 0.99 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8102444 | 0.99 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4145314 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4157043 | 0.91 | ADORA2A (0.84) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4151696 | 0.91 | ADORA2A (0.84) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4156738 | 0.91 | ADORA2A (0.84) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4152507 | 0.91 | ADORA2A (0.84) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4152512 | 0.91 | ADORA2A (0.84) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| CN-101072787-A | Substituted adenines and the use thereof | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| EP-0515514-B1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | DISCOVERY THERAPEUTICS INC (US) | 2000-08-30 | — | — | EP | disclosed |
| US-RE36494-E | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents | DISCOVERY THERAPEUTICS, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0515514-A4 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | — | 1993-01-13 | — | — | EP | disclosed |
| EP-0515514-A1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | WHITBY RESEARCH, Inc. (US) | 1992-12-02 | — | — | EP | disclosed |
| US-5140015-A | Racemic mixture for inducing an adenosine response in humans and animals | WHITBY RESEARCH, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1991013082-A1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | WHITBY RESEARCH, INC. (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA2A 33/4885ADORA2B 46/4885ADORA3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.